The company announced the clinical trial in a news release earlier this year

diabetes-g789e60cf2_1920

The Know Labs team continues to focus on delivering the first FDA-cleared non-invasive blood glucose monitoring device. (Credit: Steve Buissinne from Pixabay)

Know Labs, Inc. (OTCQB: KNWN), an emerging developer of non-invasive medical diagnostic technology, today released a video update on the IRB-approved internal trial the Company has been conducting at its laboratory in Seattle.

The two-minute video breaks down the trial process, while Know Labs Chief Product Officer Steve Kent explains the protocol for the internal clinical trial and reviews its primary goal, to further refine the algorithm that controls and enables Bio-RFID to identify and measure glucose in the body accurately. The company announced the clinical trial in a news release earlier this year.

“Our clinical team collects thousands of data points each time the test is performed. Once the data is validated, Know Labs data scientists apply complex methodologies to improve the algorithm’s accuracy and stability,” said Steve Kent. “It is a lot of work, but we are taking every step to ensure we get this right and create a production-ready algorithm for the clinical trials we will use in the application to the FDA.”

The Know Labs team continues to focus on delivering the first FDA-cleared non-invasive blood glucose monitoring device.

Source: Company Press Release